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Abstract
Background: Mitochondrial disease can manifest as multi-organ disorder, often with neurological dysfunction.
Cerebellar ataxia in isolation or in combination with other features can result from mitochondrial disease yet
genetic testing using blood DNA is not sufficient to exclude this as a cause of ataxia. Muscle biopsy is a useful
diagnostic tool for patients with ataxia suspected of mitochondrial disease. Our aim was to determine specific
patient selection criteria for muscle biopsy to see how frequent mitochondrial mutations are responsible for
progressive ataxia. We performed a two centre retrospective review of patients with unexplained progressive
ataxia who underwent muscle biopsy for suspected mitochondrial disease between 2004 and 2014 (Sheffield and
Newcastle Ataxia Centres).
Results: A total of 126 patients were identified; 26 assessed in Newcastle and 100 in Sheffield. Twenty-four patients
had pure ataxia and 102 had ataxia with additional features. The total number of patients with histologically
suspected and/or genetically confirmed mitochondrial disease was 29/126 (23 %).
Conclusions: A large proportion of patients (23 %) with progressive ataxia who underwent muscle biopsy were
found to have features of mitochondrial dysfunction, with molecular confirmation in some. Muscle biopsy is a
helpful diagnostic tool for mitochondrial disease in patients with progressive ataxia.
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Background
Mitochondrial disease represents a heterogeneous group
of disorders caused by a primary defect of mitochondrial
respiratory chain dysfunction. They present at any age
and are a result of mutations either in the nuclear or
mitochondrial DNA (mtDNA) [1]. Mitochondrial disease
can manifest as a multi-organ disorder frequently
presenting with neurological dysfunction with deafness,
myopathy, ataxia, ptosis, ophthalmoplegia and retinitis
pigmentosa amongst the most common neurological fea-
tures encountered [2]. Many genetically-characterised
mitochondrial disorders manifest with a combination of
clinical features comprising distinct syndromes such as
Kearns-Sayre syndrome (KSS) [3], chronic progressive
external ophthalmoplegia (CPEO) [3], mitochondrial
encephalopathy, lactic acidosis and stroke like episodes
(MELAS) [4], myoclonic epilepsy with ragged red fibres
(MERRF) [5], neurogenic weakness with ataxia and
retinitis pigmentosa (NARP) and Leigh syndrome (LS) [6].
Even within these syndromes, clinical variability may exist
and not all patients fit into a distinct clinical phenotype.
More of a diagnostic challenge is the clinical scenario
where a limited number of such features are present
with or without a family history. This is particularly true
in patients presenting with cerebellar ataxia. Despite
ataxia being a recognised feature in some of the
well-characterised mitochondrial syndromes such as
MELAS, MERRF, NARP, POLG-related ataxia neuropathy
spectrum (ANS) [7] that includes mitochondrial recessive
ataxia syndrome (MIRAS) and sensory ataxia neuropathy
dysarthria and ophthalmoplegia (SANDO), genetic testing
for the above mutations is not always positive. This is be-
cause the specific mutation may not have been tested for,
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or because the mtDNA mutation is not detectable in
blood. In this context, muscle biopsy can be a useful
investigation in the diagnostic work up of suspected cases
as it can demonstrate histological and histochemical
abnormalities suggestive of an underlying mitochondrial
biochemical defect [8]. There are, however no specific
guidelines for selecting patients with progressive ataxia for
a muscle biopsy. The role and diagnostic yield of a muscle
biopsy in any patient with progressive ataxia of undeter-
mined cause requires clarification.
A large two-centre collaboration between the Sheffield
and Newcastle Ataxia Centres and the Newcastle Highly
Specialised Service Mitochondrial Diagnostic laboratory
led to a retrospective review of clinical, genetic and
muscle histological characteristics of all patients with
progressive ataxia of undetermined cause who under-
went muscle biopsy to specifically investigate a possible
mitochondrial aetiology between 2004 and 2014. There
are only 4 such ataxia centres in the UK, receiving refer-
rals from all over the UK. The diagnostic yield for such
referrals where a diagnosis has not been reached by the
referring centre is approximately 50 %. The aim of this
retrospective review was twofold: firstly to establish the
frequency of mitochondrial disease as the cause of pro-
gressive ataxia and secondly to identify any additional
clinical characteristics that are likely to indicate which
patients require muscle biopsy as part of the diagnostic
work-up.
Results
Clinical characteristics
A total of 126 patients were included; 26 assessed in
Newcastle and 100 in Sheffield. There were no statistically
significant differences in the frequency of major clinical
features between the Newcastle and Sheffield cohorts
(see Table 1) hence the results are presented for the
group of 126 patients as a whole. The mean age at the
time of the muscle biopsy was 52 years. The male to
female ratio was 72 to 54. Patients displaying the
‘ataxia plus’ phenotype dominated the group with 102
having ‘ataxia plus’ vs. 24 having ‘pure ataxia’ (see Table 2).
Family history was present in 50/126 (40 %) of patients.
Of the patients with a family history, 21/50 (42 %) had
autosomal recessive inheritance, 14/50 (28 %) autosomal
dominant and 15/50 (30 %) maternal.
Brain imaging
Magnetic resonance imaging was abnormal in 104 out of
117 patients scanned; a normal scan was reported in 13
patients; cerebellar atrophy was demonstrated in 92
patients. The remaining 12 abnormal scans showed
predominantly small vessel ischaemia in keeping with
Table 1 Clinical characteristics of the Sheffield and
Newcastle cohorts
Newcastle Sheffield All
n = 26 n = 100 n = 126
Clinical
Mean age at muscle biopsy (range) 50 (22–76) 53 (18–78) 52 (18–78)
Sex (M:F) 14:12 58:42 72:54
Family history 8 (31 %) 42 (42 %) 50 (40 %)
Phenotype (pure ataxia: ataxia plus) 4:22 20:80 24:102
Table 2 Additional clinical features in patients with histologically
suspected or genetically confirmed mitochondrial disease
Patient groups
Histologically
suspected
mitochondrial
disease without
genetic
confirmation
Genetically
confirmed
mitochondrial
disease
Unlikely
mitochondrial
disease
remaining
patients
Total 21/126 (17 %) 11/126 (9 %) 94/126 (75 %)
Family History 12/21 (57 %) 2/11 (18 %) 36/94 (38 %)
Autosomal recessive 5/21 (24 %) 0/11 (0 %) 16/94 (17 %)
Autosomal dominant 3/21 (14 %) 1/11 (9 %) 10/94 (11 %)
Maternal 4/21 (19 %) 1/11 (9 %) 10/94 (11 %)
No Family History 9/21 (43 %) 9/11 (82 %) 58/94 (62 %)
Pure Ataxia 3/21 (14 %) 0/11 (0 %) 21/94 (22 %)
Ataxia Plus
(Associated features)
18/21 (86 %) 11/11 (100 %) 73/94 (78 %)
Neurological
Deafness 3/21 (14 %) 5/11 (45 %) 19/94 (20 %)
Dysphagia 0/21 (0 %) 2/11 (18 %) 0/94 (0 %)
Developmental
problems
1/21 (5 %) 2/11 (18 %) 11/94 (12 %)
Cognitive deficits 2/21 (10 %) 2/11 (18 %) 6/94 (6 %)
Dystonia 2/21 (10 %) 0/11 (0 %) 2/94 (2 %)
Myoclonus 2/21 (10 %) 3/11 (27 %) 14/94 (15 %)
Epilepsy 2/21 (10 %) 2/11 (18 %) 12/94 (13 %)
Peripheral neuropathy 5/21 (24 %) 1/11 (9 %) 21/94 (22 %)
Spastic paraparesis 7/21 (33 %) 2/11 (18 %) 7/94 (7 %)
Myopathy 2/21 (10 %) 1/11 (9 %) 8/94 (9 %)
Endocrine
Impaired
glycaemia/DM
1/21 (5 %) 3/11 (27 %) 8/94 (9 %)
Ocular
Ptosis 0/21 (0 %) 0/11 (0 %) 3/94 (3 %)
Ophthalmoplegia 0/21 (0 %) 1/11 (9 %) 6/94 (6 %)
Optic atrophy 0/21 (0 %) 1/11 (9 %) 2/94 (2 %)
Retinitis pigmentosa 0/21 (0 %) 2/11 (18 %) 2/94 (2 %)
Other
Short stature 1/21 (5 %) 1/11 (9 %) 1/94 (1 %)
Nephropathy 0/21 (0 %) 1/11 (9 %) 1/94 (1 %)
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age but no features to suggest mitochondrial disease.
There were no differences on imaging between patients
with and those without mitochondrial disease.
Muscle analysis
Of the 126 patients with ataxia who underwent a muscle
biopsy, 30 were identified on initial histopathological as-
sessment as having features suggestive of mitochondrial
disease. Three of these patients were subsequently
found, on genetic testing, to have SPG7 and were
therefore excluded from the mitochondrial group, leav-
ing 27 patients in total with histologically suspected
mitochondrial disease. Two additional patients were
found to have mitochondrial disease on genetic testing
despite normal muscle histology. Of these 29 patients,
eleven had mitochondrial disease confirmed on further
genetic analysis, either with the presence of mtDNA
rearrangements or deletions (n = 3) or with the iden-
tification of specific mutations (m.8719G > A, p. Gly65*
(MTATP6), m.9185 T > C, p. Leu220Pro (MTATP6),
m.3243A >G (MTTL1), m.7510 T >C (MTTS1), c.811C >T,
p.R271C/c.911G >A, pA304T (CABC1/ADCK3) as well
as compound heterozygosity for two sequence variants in
the POLG gene (c.1232 T > C, p. (Leu411Pro) and
c.1721G >A, p. (Arg574Gln)). Thus the total number of
patients with histologically suspected and/or genetically
confirmed mitochondrial disease was 29/126 (23 %).
Discussion
This retrospective review of a large number of patients
(126) with progressive cerebellar ataxia who underwent
muscle biopsy suggests that mitochondrial disease is
likely to be a common cause of progressive cerebellar
ataxia (up to 23 %) and that muscle biopsy is an im-
portant diagnostic test in such cases.
Patients with the ‘ataxia plus’ phenotype constituted
the majority of patients referred for a muscle biopsy.
91 % of patients with histologically suspected/genetically
confirmed mitochondrial disease had ‘ataxia plus’ as
opposed to 9 % of patients with pure ataxia. Additional
features such as deafness, impaired glycaemic control/
diabetes, myoclonus, neuropathy or spastic paraparesis
were therefore more likely to be associated with the
diagnosis of mitochondrial disease.
Attention to the family history can be useful in inter-
preting muscle biopsy findings as well as directing and
validating later genetic results. The presence of a family
history and the mode of inheritance did not, however,
predict the likelihood of mitochondrial disease in these
patients. There are several possible reasons for this,
including the late onset of the disorder in these families
(and possible death from other causes in preceding
relatives), and the recent onset of the mutations.
Genetic confirmation in patients with histological and
histochemical changes suggestive of mitochondrial path-
ology was achieved in 9/27 (33 %) patients. In 2 patients
a genetic diagnosis of mitochondrial disease was made
even in the presence of normal histological changes in
the muscle, suggesting that normal muscle histology and
histochemistry does not exclude mitochondrial disease.
It is also worth noting that patients with SPG7 can have
muscle histological abnormalities suggestive of mito-
chondrial dysfunction, something that has been pre-
viously described [9]. For the remaining undiagnosed
patients, the increasing availability of high-output whole
exome sequencing will likely have a role in detecting
pathogenic variants underlying ataxia syndromes [10, 11].
The use of muscle biopsy as a means of targeting down-
stream genetic analysis will expedite the identification of
known mutations as well as providing evidence of a
biochemical defect consistent with the genetic defect, thus
adding weight to the presumed pathogenic nature of novel
genetic variants.
At the time of review, 50 patients with normal muscle
biopsies still had no specific diagnosis for their ataxia.
Twenty-six of these patients (52 %) had a family history
and presumed genetic ataxia is likely to be the cause.
With the introduction of next generation sequencing a
diagnosis was achieved in some of these patients as
follows: 2 additional patients with SPG7, 2 patients with
Niemann-Pick Type C [12], one patient with episodic
ataxia type 2 [13], one patient with ataxia telangiectasia
[14], one patient with ARSACS [15], 2 patients with
SCA14 [16], one patient with SCA28 [17] and one
patient with SCA35 [18]. If we are to exclude all the
above patients where a diagnosis was eventually achieved
the prevalence of mitochondrial disease becomes as high
as 43 %. These findings emphasise the need for regular
review and diagnostic re-evaluation of all patients with
progressive ataxia, something that is the norm in UK
ataxia centres.
Methods
Patient selection
Adult patients (>18 years) with unexplained cerebellar
ataxia referred to a specialist ataxia clinic at either
neuroscience centre (Sheffield or Newcastle) who under-
went a muscle biopsy between 2004–2014 were included.
Only those who had muscle biopsies to investigate pro-
gressive ataxia of undetermined cause following extensive
investigations were included in this 10-year study period.
Those with primary myopathy or other neurological
features in the absence of cerebellar ataxia were excluded.
Clinical evaluation
Clinical assessment and investigations were the same at
both sites. A full history and examination was conducted
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allowing patients to be categorised as a ‘pure ataxia’ pheno-
type or an ‘ataxia plus’ phenotype (ataxia with associated
features, e.g. peripheral neuropathy, epilepsy, diabetes).
The additional clinical features were grouped according to
systems (neurological, endocrine, ocular and other). Ex-
tensive investigations to determine the aetiology of ataxia
were performed prior to the muscle biopsy. Such tests,
depending on clinical indications, included blood cell
counts, biochemistry, thyroid function, serology for
coeliac disease, vitamin A, B12, E; metabolic screen for
acyl-carnitines, urinary organic acids, very long chain fatty
acids, phytanic acids, lysosymal enzymes, lipoproteins,
serum electrophoresis, copper, caeruloplasmin, ferritin
and iron amongst others. The presence of a family his-
tory including mode of inheritance was documented.
Volumetric 3 T MR imaging of the cerebellum was under-
taken in patients with cerebellar ataxia using a 3-T system
(Philips ACHIEVA 3.0 T Best, Netherlands). The final
diagnosis at the time of review was also noted.
Genetic testing
Prior to performing a muscle biopsy, all patients had blood
DNA genetic testing for common mitochondrial syn-
dromes (MELAS, MERRF, NARP) and in selected cases
when clinically indicated, mutations in the mitochondrial
DNA polymerase gamma (POLG) gene. In addition,
testing to exclude other ataxia syndromes was performed,
including spinocerebellar ataxias (SCA1,2,3,6,7,12 and 17)
and Friedreich’s ataxia (FA). Additional genetic tests
including, for example, DRPLA, fragile X, ataxia occulo-
motor apraxia, episodic ataxias, SPG7 screening were
carried out if clinically indicated.
Muscle biopsy
(a) Routine histopathology
Muscle biopsies were performed using an open
muscle (deltoid or quadriceps) biopsy technique.
A portion of tissue was immediately frozen
(liquid nitrogen cooled isopentane) in transverse
orientation and cryosectioned (10 μm) in
accordance with standard laboratory enzyme
histochemistry and histology protocols. A second
portion of tissue was stored at − 80 °C for molecular
genetic studies. Routine histological stains used
included haematoxylin and eosin (H & E), modified
gomori trichrome and a stain for lipid (oil red O or
sudan black); periodic acid Schiff (with and
without diastase), nicotinamide adenosine
dinucleotide–tetrazolium reductase (NADH–TR),
cytochrome c oxidase (COx) and succinate
dehydrogenase (SDH) histochemical reactions were
undertaken. Histochemistry for COx and SDH were
performed either as individual preparations or as a
sequential reaction in which absence of COx
reactivity in COx-deficient fibres allows the SDH
tetrazolium reaction product to be visualised.
Histological characterisation focused on identifying
fibre size and type, architectural changes, signs of
necrosis or regeneration, interstitial variations and
immunohistochemical findings (in particular ragged
red fibres, fibres with lipid accumulation and
COx-deficient fibres). The percentage of
COx-deficient fibres vs age was taken into
consideration (COx-deficient fibres are extremely
rare in normal individuals under the age of 50 years,
therefore for patients >60 years of age we considered
histochemical support of a mitochondrial aetiology if
the frequency of COx-deficient fibres exceeded 2 %
of the total biopsy) [19, 20]. Muscle biopsies
obtained in Sheffield also underwent electron
microscopy (EM) examination to look for additional
evidence of mitochondrial disease such as abnormal
mitochondrial accumulation, dysmorphic organelles
and paracrystalline inclusions.
(b) Mitochondrial respiratory chain enzymes and
mtDNA genetics
Spectrophotometric measurements of individual
respiratory chain enzyme activities and the matrix
enzyme marker citrate synthase were performed as
described [21]. Molecular genetic analysis was
performed in all muscle biopsy samples showing
histopathological signs of mitochondrial disease.
Long-range polymerase chain reaction assays were
used to screen for large-scale mitochondrial DNA
(mtDNA) rearrangements [22], whilst in some cases
sequencing of the entire mitochondrial genome was
undertaken.
Conclusion
 Mitochondrial disease is likely to be the cause of
ataxia in up to 23 % of patients with otherwise
idiopathic, progressive cerebellar ataxia. In such
cases muscle biopsy is an important diagnostic test.
 Additional features such as deafness, impaired
glycaemic control/diabetes, myoclonus, neuropathy
or spastic paraparesis are more likely to be seen in
the context of mitochondrial disease.
 Pure ataxia is rarely due to mitochondrial disease.
 Normal muscle histology and histochemistry does
not exclude mitochondrial disease.
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